Quantity
Price
$120.64
100 available
This strength’s Certificate of Analysis isn’t published yet — add to cart will be enabled once the lab report is available.
FOX04-DRI
From $120.64to $904.77
For laboratory research use only. Not for human or animal use, consumption, diagnosis, treatment, or disease prevention.
This item is available only through approved account access.
Product Specifications
- Lot Number
- —
- Purity
- —
- Storage Temp
- 36°F to 46°F
For Research Use Only. Not for human or animal administration. Not intended to diagnose, treat, cure, or prevent any disease. Sold for laboratory research purposes only.
Documentation
Certificates of Analysis are supplied with each product lot where applicable.
Certificate of Analysis (COA)
Documentation will be available once product lots are received and tested.
All products currently listed on this site are for research purposes only.
COA Library
Published Certificates of Analysis for FOX04-DRI. New deliveries are added as their batches are released.
No released COA for this strength yet
Reports appear here once a batch for this strength has been released.
Research Data
Chemical & Structural Identifiers
- Chemical Name (IUPAC)
- D-retro-inverso peptide antagonist of the forkhead box O4 (FOXO4) and tumor suppressor p53 interaction, fused to a cell-penetrating D-retro-inverso Tat sequence.
- CAS Registry Number
- 2249767-45-5
- PubChem CID
- 137700201
- Molecular Formula
- C226H377N83O63
- Molecular Weight
- 5354.91 Da (5358.20 g/mol average)
- Salt / Counter-Ion
- Supplied as a lyophilized trifluoroacetate (CF3COO-) or acetate (CH3COO-) salt.
- Synonyms
- FOXO4-DRI, FOXO4-D-Retro-Inverso, Proxofim, FOXO4-p53 Interfering Peptide.
Analytical & COA Specifications
- Analytical Purity (RP-HPLC)
- ≥ 98.0% area normalization under UV detection at λ = 214 nm and 280 nm (tryptophan detection).
- Identity Confirmation (MALDI-TOF / High-Resolution ESI-MS)
- Theoretical mass [M+H]+ = 5359.2 Da; observed mass-to-charge ratio matches expected multivalent charge envelopes ([M+4H]4+, [M+5H]5+, [M+6H]6+) within ± 1.0 Da of theoretical deconvolution.
- Residual Moisture (Karl Fischer Titration)
- ≤ 3.5% water content.
- Endotoxin Screening (LAL Assay)
- < 1.0 EU/mg (Limulus Amebocyte Lysate per USP <85>).
- Sterility Validation
- USP <71> compliant (no microbial turbidity observed in fluid thioglycollate/soybean-casein digest broths).
- Physical Characterization
- Dense, white to off-white lyophilized solid cake/powder.
Handling & Stability
Storage. Store dry solid desiccated at -20°C to -80°C, protected from atmospheric moisture and direct light.
Solubility. Soluble in sterile laboratory-grade deionized water (≥ 10 mg/mL), sterile Phosphate-Buffered Saline (PBS, pH 7.4), or sterile dilute 0.1% acetic acid for stock stabilization in in vitro assay applications.
- D-Enantiomeric Stability & Handling: Constructed entirely with D-amino acids in reverse topological sequence, conferring high stability against standard laboratory endopeptidases and carboxypeptidases; aliquot into single-use fractions to eliminate degradation from repeated freeze-thaw cycles.
Mechanism & Literature
Designed to competitively disrupt the protein-protein interaction (PPI) between the forkhead box transcription factor FOXO4 and the tumor suppressor p53. Under baseline conditions in senescent cells, FOXO4 sequesters p53 in the nucleus, repressing apoptotic triggers. FOXO4-DRI binds to the regulatory domain, displacing p53 and permitting its mitochondrial translocation to induce selective caspase-3/7/9-dependent apoptosis.
Cellular Pathways Investigated: Extensively documented in in vitro cellular senescence models (e.g., ionizing radiation-induced or doxorubicin-induced senescent IMR90 human fibroblasts and senescent primary endothelial cells) to evaluate selective senolysis, downregulation of the senescence-associated secretory phenotype (SASP; IL-6, IL-8, MMP-3), and quantification of cell viability ratios between senescent vs. non-senescent control cultures.
References (2)
- Baar, M. P., et al. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, 169(1), 132–147.
- Huang, C. H., et al. (2021). FOXO4-p53 interaction as a mechanistic target in cellular senescence modeling. Biochemical Society Transactions, 49(3), 1187–1197.
Technical Laboratory FAQs
What is the functional design principle behind the D-retro-inverso (DRI) structure of FOXO4-DRI?
The peptide synthesizes the reverse sequence of the native FOXO4 interaction motif using D-enantiomeric amino acids, preserving side-chain spatial topology while eliminating susceptibility to enzymatic cleavage by L-amino acid-specific proteases in cell culture assays.
How does FOXO4-DRI trigger selective apoptosis in senescent cell lines in vitro?
FOXO4-DRI disrupts the endogenous FOXO4-p53 complex in senescent cells, liberating p53 to translocate to the mitochondria, which initiates cytochrome c release and caspase cascade activation without triggering apoptosis in non-senescent cells.
What solvent conditions are recommended for preparing in vitro FOXO4-DRI stock assays?
Sterile deionized water or sterile PBS (pH 7.4) is suitable for standard biological dilutions. For higher-concentration stock preparations, a sterile 0.1% acetic acid vehicle provides enhanced peptide solubility prior to cell culture media integration.
For Research Use Only. Not for human or animal administration. Not intended to diagnose, treat, cure, or prevent any disease. Sold for laboratory research purposes only.